Edition:
United Kingdom

Sartorius Stedim Biotech SA (STDM.PA)

STDM.PA on Paris Stock Exchange

119.10EUR
1:21pm BST
Change (% chg)

€-0.70 (-0.58%)
Prev Close
€119.80
Open
€119.80
Day's High
€121.50
Day's Low
€118.90
Volume
30,052
Avg. Vol
67,457
52-wk High
€121.50
52-wk Low
€73.45

Latest Key Developments (Source: Significant Developments)

Sartorius Stedim Biotech Q1 Sales Revenue Up 19.3% To 342.9 Million Euros
Thursday, 18 Apr 2019 

April 18 (Reuters) - SARTORIUS STEDIM BIOTECH SA ::Q1 SALES REVENUE UP 19.3%; ORDER INTAKE UP 18.7%; EARNINGS MARGIN 28.6%.GUIDANCE FOR 2019 CONFIRMED.SALES REVENUE INCREASED AGAINST RELATIVELY MODERATE COMPARABLES IN THE PRIOR-YEAR QUARTER BY 19.3% TO 342.9 MILLION EUROS.Q1 ORDER INTAKE ALSO SAW A SIGNIFICANT UPTICK, RISING 18.7% TO 381.3 MILLION EUROS.Q1 UNDERLYING EBITDA1 ROSE OVERPROPORTIONATELY RELATIVE TO SALES BY 32.5% TO 98.1 MILLION EUROS.THE Q1 RESPECTIVE MARGIN REACHED 28.6% (Q1 2018: 26.3%).Q1 RELEVANT NET PROFIT AFTER NON-CONTROLLING INTEREST FOR THE GROUP SURGED BY 32.9% TO 62.6 MILLION EUROS.WE EXPECT THAT GROWTH RATES WILL NORMALIZE OVER THE COURSE OF THE YEAR. ON THIS BASIS WE CONFIRM OUR 2019 FULL-YEAR GUIDANCE - CEO.SEES CONSOLIDATED SALES REVENUE IS PROJECTED TO GROW BY ABOUT 7% TO 11% IN 2019.EXPECTS COMPANY'S UNDERLYING 2019 EBITDA MARGIN TO INCREASE BY SLIGHTLY MORE THAN ONE PERCENT.  Full Article

Sartorius Stedim Biotech FY Revenue Up At 1.21 Billion Euros
Tuesday, 19 Feb 2019 

Feb 19 (Reuters) - SARTORIUS STEDIM BIOTECH SA ::FY SALES REVENUE ROSE IN CONSTANT CURRENCIES BY 13.7% TO 1,212.2 MILLION EUROS (REPORTED +12.1%)..SARTORIUS STEDIM BIOTECH EXPECTS CONTINUED PROFITABLE GROWTH IN 2019.WITHOUT THESE CHANGES, SALES GROWTH WOULD PROBABLY BE APPROXIMATELY 3 PERCENTAGE POINTS HIGHER..IN 2019, CONSOLIDATED SALES REVENUE IS PROJECTED TO GROW BY ABOUT 7% TO 11%.EBITDA MARGIN WILL INCREASE BY SLIGHTLY MORE THAN ONE PERCENTAGE POINT OVER THE PRIOR-YEAR FIGURE OF 28.2%.THE RATIO OF CAPITAL EXPENDITURES TO SALES REVENUE IS PROJECTED TO BE AROUND 11%, DOWN FROM YEAR-EARLIER FIGURE OF 14.6%..DISORDERLY EXIT OF THE UNITED KINGDOM FROM THE EU MAY HAVE A CERTAIN IMPACT ON OUR SUPPLY CHAIN.RELIABLE FORECAST OF POSSIBLE EFFECTS OF BREXIT CANNOT BE GIVEN AT THE PRESENT TIME.  Full Article

Sartorius Stedim Biotech FY Double Digit Sales And Earnings Growth
Tuesday, 29 Jan 2019 

Jan 29 (Reuters) - SARTORIUS STEDIM BIOTECH SA ::SARTORIUS STEDIM BIOTECH GROWS BY DOUBLE DIGITS IN SALES AND EARNINGS IN 2018 – POSITIVE OUTLOOK FOR 2019.AMBITIOUS GUIDANCE FOR 2019 BACKED BY STRONG ORDER INTAKE.2018 GROUP SALES REVENUE UP 13.7%; EARNINGS MARGIN(1)) UP BY 0.9 PERCENTAGE POINTS TO 28.2%.  Full Article

Lonza, Sartorius Modify Relationship For Supply Of Cell Culture Media
Thursday, 15 Nov 2018 

Nov 15 (Reuters) - Lonza And Sartorius Stedim Biotech Modify Relationship For Supply Of Cell Culture Media ::SARTORIUS STEDIM BIOTECH WILL CONTINUE TO OFFER LONZA MEDIA AND BUFFER PRODUCTS BUT UNDER A NON-EXCLUSIVE AGREEMENT.  Full Article

Sartorius Stedim Biotech 9 Month Net Profit Rises To 160.7 Million Euros
Tuesday, 23 Oct 2018 

Oct 23 (Reuters) - SARTORIUS STEDIM BIOTECH SA ::9M GROUP SALES REVENUE UP 13.8%; ORDER INTAKE UP 14.5%; EARNINGS MARGIN 28.1%.2018 GUIDANCE CONFIRMED.FY SALES REVENUE GROWTH NOW PROJECTED TO BE IN UPPER RANGE OF PREVIOUSLY TARGETED BANDWIDTH OF 11% TO 14%.FY UNDERLYING EBITDA MARGIN CONTINUES TO BE EXPECTED AT AROUND 28.0%.9 MONTH NET PROFIT EUR 160.7 MILLION VERSUS EUR 130.8 MILLION YEAR AGO.9M UNDERLYING EBITDA 251.4 MILLION EUROS.  Full Article

Sartorius Stedim Biotech And Repligen Corporation Partner On Next-Gen Perfusion-Enabled Bioreactors
Tuesday, 4 Sep 2018 

Sept 4 (Reuters) - SARTORIUS STEDIM BIOTECH SA ::SARTORIUS STEDIM BIOTECH SA - SARTORIUS STEDIM BIOTECH AND REPLIGEN CORPORATION PARTNER TO INTRODUCE NEXT-GENERATION PERFUSION-ENABLED BIOREACTORS.  Full Article

Sartorius Stedim Biotech H1 Net Profit Up At 103.7 Million Euros
Tuesday, 24 Jul 2018 

July 24 (Reuters) - SARTORIUS STEDIM BIOTECH SA ::BUSINESS FIGURES FOR THE FIRST HALF OF 2018: SARTORIUS STEDIM BIOTECH RECORDS DOUBLE-DIGIT GROWTH IN SALES AND PROFIT.H1 GROUP REVENUE UP 11.1%, ORDER INTAKE UP 11.8% AND EARNINGS(1)) UP 11.1%.IN FIRST HALF OF 2018, SALES REVENUE ROSE BY 11.1% IN CONSTANT CURRENCIES (REPORTED: +7.3%) FROM 545.9 MILLION EUROS TO 585.7 MILLION EUROS.MANAGEMENT HAS RAISED ITS FORECAST FOR FULL YEAR: IN CONSTANT CURRENCIES, SALES REVENUE IS NOW ANTICIPATED TO INCREASE BY ABOUT 11% TO 14%.FY SALES REVENUE IS NOW ANTICIPATED TO INCREASE BY ABOUT 11% TO 14% VERSUS PREVIOUS GUIDANCE OF 7% TO 10%..2018 UNDERLYING EBITDA MARGIN IS NOW PROJECTED TO REACH AROUND 28.0%.H1 NET PROFIT EUR 103.7 MILLION VERSUS EUR 89.1 MILLION YEAR AGO.H1 UNDERLYING EBITDA WAS UP BY 11.1%, FROM 146.5 MILLION EUROS TO 162.8 MILLION EUROS.H1 SALES REVENUE EUR 585.7 MILLION VERSUS EUR 546.7 MILLION YEAR AGO.  Full Article

Sartorius Stedim Biotech And Siemens Sign Long-Term Cooperation Agreement In Area Of Automation
Tuesday, 12 Jun 2018 

June 12 (Reuters) - Sartorius Stedim Biotech Sa ::SARTORIUS STEDIM BIOTECH AND SIEMENS SIGN LONG-TERM COOPERATION AGREEMENT IN AREA OF AUTOMATION.SIEMENS BECOMES A PREFERRED SUPPLIER FOR AUTOMATION SOLUTIONS.PRODUCT PORTFOLIO OF SARTORIUS STEDIM BIOTECH TO FEATURE A GLOBALLY STANDARDIZED AUTOMATION PLATFORM IN FUTURE.PRODUCT PORTFOLIO OF SARTORIUS STEDIM BIOTECH TO FEATURE A GLOBALLY STANDARDIZED AUTOMATION PLATFORM IN FUTURE.  Full Article

Sartorius Stedim Biotech Net Profit Up at 47.1 Million Euros
Tuesday, 24 Apr 2018 

April 24 (Reuters) - SARTORIUS STEDIM BIOTECH SA ::CONFIRMS 2018 TARGETS.IN Q1 INCREASED ITS SALES REVENUE IN CONSTANT CURRENCIES BY 9.8% (REPORTED 4.6%) TO 281.1 MILLION EUROS..Q1 UNDERLYING EBITDA INCREASED 3.0%, AND REACHED 74.0 MILLION EUROS.Q1 CAPEX RATIO OF 2018 WAS 9.2%.Q1 ORDER INTAKE INCREASED BY 9.0% IN CONSTANT CURRENCIES (REPORTED 3.9 PERCENT).EQUITY RATIO ET END OF PERIOD 62.8% (DEC. 31, 2017: 62.6%).Q1 EBITDA EUR 74.0 MILLION VERSUS EUR 71.9 MILLION YEAR AGO.Q1 NET PROFIT EUR 47.1 MILLION VERSUS EUR 44.0 MILLION YEAR AGO.  Full Article

Sartorius Stedim Biotech And Penn State University Entered Into Collaborative Partnership
Monday, 16 Apr 2018 

April 16 (Reuters) - SARTORIUS STEDIM BIOTECH SA ::SARTORIUS STEDIM BIOTECH AND PENN STATE UNIVERSITY ENTERED INTO COLLABORATIVE PARTNERSHIP TO ADVANCE MULTIDISCIPLINARY TEACHING AND RESEARCH IN BIOTECHNOLOGY.  Full Article

European shares cautious ahead of PMI data

April 18 European shares ticked lower in early deals on Thursday, as investors cautiously awaited manufacturing data to gauge the health of euro zone economies ahead of the Easter holiday.